BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 27922538)

  • 1. The role of 68Ga-DOTA-NOC PET/CT in evaluating neuroendocrine tumors: real-world experience from two large neuroendocrine tumor centers.
    Haidar M; Shamseddine A; Panagiotidis E; Jreige M; Mukherji D; Assi R; Abousaid R; Ibrahim T; Haddad MM; Vinjamuri S
    Nucl Med Commun; 2017 Feb; 38(2):170-177. PubMed ID: 27922538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroendocrine tumor imaging with 68Ga-DOTA-NOC: physiologic and benign variants.
    Kagna O; Pirmisashvili N; Tshori S; Freedman N; Israel O; Krausz Y
    AJR Am J Roentgenol; 2014 Dec; 203(6):1317-23. PubMed ID: 25415711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual tracer functional imaging of gastroenteropancreatic neuroendocrine tumors using 68Ga-DOTA-NOC PET-CT and 18F-FDG PET-CT: competitive or complimentary?
    Naswa N; Sharma P; Gupta SK; Karunanithi S; Reddy RM; Patnecha M; Lata S; Kumar R; Malhotra A; Bal C
    Clin Nucl Med; 2014 Jan; 39(1):e27-34. PubMed ID: 24217539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gallium-68-DOTA-NOC PET/CT of patients with gastroenteropancreatic neuroendocrine tumors: a prospective single-center study.
    Naswa N; Sharma P; Kumar A; Nazar AH; Kumar R; Chumber S; Bal C
    AJR Am J Roentgenol; 2011 Nov; 197(5):1221-8. PubMed ID: 22021518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of unusual neuroendocrine tumours by means of 68Ga-DOTA-NOC PET.
    Fanti S; Ambrosini V; Tomassetti P; Castellucci P; Montini G; Allegri V; Grassetto G; Rubello D; Nanni C; Franchi R
    Biomed Pharmacother; 2008 Dec; 62(10):667-71. PubMed ID: 18358680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is ⁶⁸Ga-DOTA-NOC PET/CT indicated in patients with clinical, biochemical or radiological suspicion of neuroendocrine tumour?
    Ambrosini V; Campana D; Nanni C; Cambioli S; Tomassetti P; Rubello D; Fanti S
    Eur J Nucl Med Mol Imaging; 2012 Aug; 39(8):1278-83. PubMed ID: 22584487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. (68)Ga-DOTA-NOC PET/CT in comparison with CT for the detection of bone metastasis in patients with neuroendocrine tumours.
    Ambrosini V; Nanni C; Zompatori M; Campana D; Tomassetti P; Castellucci P; Allegri V; Rubello D; Montini G; Franchi R; Fanti S
    Eur J Nucl Med Mol Imaging; 2010 Apr; 37(4):722-7. PubMed ID: 20107793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Direct comparison of (68)Ga-DOTA-TOC and (18)F-FDG PET/CT in the follow-up of patients with neuroendocrine tumour treated with the first full peptide receptor radionuclide therapy cycle.
    Nilica B; Waitz D; Stevanovic V; Uprimny C; Kendler D; Buxbaum S; Warwitz B; Gerardo L; Henninger B; Virgolini I; Rodrigues M
    Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1585-92. PubMed ID: 26922350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 68Ga-DOTA-NOC: a new PET tracer for evaluating patients with bronchial carcinoid.
    Ambrosini V; Castellucci P; Rubello D; Nanni C; Musto A; Allegri V; Montini GC; Mattioli S; Grassetto G; Al-Nahhas A; Franchi R; Fanti S
    Nucl Med Commun; 2009 Apr; 30(4):281-6. PubMed ID: 19247211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of [
    Yadav D; Ballal S; Yadav MP; Tripathi M; Roesch F; Bal C
    Eur J Nucl Med Mol Imaging; 2020 Apr; 47(4):860-869. PubMed ID: 31754796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 68Ga-DOTA-NOC PET/CT imaging of neuroendocrine tumors: comparison with ¹¹¹In-DTPA-octreotide (OctreoScan®).
    Krausz Y; Freedman N; Rubinstein R; Lavie E; Orevi M; Tshori S; Salmon A; Glaser B; Chisin R; Mishani E; J Gross D
    Mol Imaging Biol; 2011 Jun; 13(3):583-593. PubMed ID: 20652423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined imaging with 68Ga-DOTA-TATE and 18F-FDG PET/CT on the basis of volumetric parameters in neuroendocrine tumors.
    Abdulrezzak U; Kurt YK; Kula M; Tutus A
    Nucl Med Commun; 2016 Aug; 37(8):874-81. PubMed ID: 27096719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive value of 68Ga-DOTANOC PET/CT in patients with suspicion of neuroendocrine tumors: is its routine use justified?
    Sharma P; Arora S; Mukherjee A; Pal S; Sahni P; Garg P; Khadgawat R; Thulkar S; Bal C; Kumar R
    Clin Nucl Med; 2014 Jan; 39(1):37-43. PubMed ID: 24152621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of unknown primary neuroendocrine tumours (CUP-NET) using (68)Ga-DOTA-NOC receptor PET/CT.
    Prasad V; Ambrosini V; Hommann M; Hoersch D; Fanti S; Baum RP
    Eur J Nucl Med Mol Imaging; 2010 Jan; 37(1):67-77. PubMed ID: 19618183
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The added value of
    Kazmierczak PM; Rominger A; Wenter V; Spitzweg C; Auernhammer C; Angele MK; Rist C; Cyran CC
    Eur Radiol; 2017 Apr; 27(4):1676-1684. PubMed ID: 27436022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ga-68 DOTA-NOC uptake in the pancreas: pathological and physiological patterns.
    Krausz Y; Rubinstein R; Appelbaum L; Mishani E; Orevi M; Fraenkel M; Tshori S; Glaser B; Bocher M; Salmon A; Chisin R; Gross DJ; Freedman N
    Clin Nucl Med; 2012 Jan; 37(1):57-62. PubMed ID: 22157030
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours.
    Ambrosini V; Tomassetti P; Castellucci P; Campana D; Montini G; Rubello D; Nanni C; Rizzello A; Franchi R; Fanti S
    Eur J Nucl Med Mol Imaging; 2008 Aug; 35(8):1431-8. PubMed ID: 18418596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Impact of 68Ga-DOTATATE PET/CT Imaging on Management of Patients with Neuroendocrine Tumors: Experience from a National Referral Center in the United Kingdom.
    Skoura E; Michopoulou S; Mohmaduvesh M; Panagiotidis E; Al Harbi M; Toumpanakis C; Almukhailed O; Kayani I; Syed R; Navalkissoor S; Ell PJ; Caplin ME; Bomanji J
    J Nucl Med; 2016 Jan; 57(1):34-40. PubMed ID: 26471695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the Impact of 68Ga-DOTATATE and 18F-FDG PET/CT on Clinical Management in Patients with Neuroendocrine Tumors.
    Panagiotidis E; Alshammari A; Michopoulou S; Skoura E; Naik K; Maragkoudakis E; Mohmaduvesh M; Al-Harbi M; Belda M; Caplin ME; Toumpanakis C; Bomanji J
    J Nucl Med; 2017 Jan; 58(1):91-96. PubMed ID: 27516446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuroendocrine tumor recurrence: diagnosis with 68Ga-DOTATATE PET/CT.
    Haug AR; Cindea-Drimus R; Auernhammer CJ; Reincke M; Beuschlein F; Wängler B; Uebleis C; Schmidt GP; Spitzweg C; Bartenstein P; Hacker M
    Radiology; 2014 Feb; 270(2):517-25. PubMed ID: 24056402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.